Healthcare Global Enterprises Limited has informed the Exchange about Earnings Call Transcript.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
HCG reported Q3 FY26 revenue of INR 633 crore, up 13.4% year-on-year, with patient volume growth of 8%. Adjusted EBITDA rose 20% YoY to INR 111 crore, with margins expanding to 17.5% from 16.5%, driven by better utilization. For 9M FY26, revenue grew 16% to INR 1,893 crore and EBITDA grew 20% to INR 346 crore, with margins at 18.3% (up 60 bps). Pre-tax ROCE stood at 13.3%. The company reiterated its 15%+ revenue growth guidance (10% volume + 5% ARPP) and guided margins toward 23-24% over 3-4 years, with a 20% ROCE target over 4-5 years as existing centres mature. Capex is pegged at INR 275-280 crore for FY26 and 10-12% higher in FY27, with brownfield and greenfield expansion planned across 7-8 cities including Bangalore, Cuttack, Ahmedabad, and Vizag. A rights issue was announced via Board meeting, with management citing balance sheet strengthening as the reason.
Strong quarter with double-digit revenue and EBITDA growth, along with margin expansion, supports a positive near-term outlook for shareholders. The reaffirmed multi-year growth and margin guidance, combined with capacity expansion plans, signals management confidence, though the upcoming rights issue may cause short-term equity dilution.